{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T08:24:25Z","timestamp":1791015865290,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T00:00:00Z","timestamp":1667001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T00:00:00Z","timestamp":1667001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009169","name":"Assiut University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009169","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Afebrile chemotherapy-induced neutropenia represents a frequent clinical situation where chemotherapy protocol, patient\u2019s comorbidities, and disease status determine the risk of infection hence the management plan. Internationally distributed, this questionnaire aims to evaluate the routine practice and the impact of the COVID-19 pandemic on afebrile chemotherapy-induced neutropenia management.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Material and methods<\/jats:title>\n                <jats:p>Coordinators from Egypt, Morocco, Azerbaijan, and Russia developed a 12-item questionnaire using Google forms to explore how oncologists deal with afebrile chemotherapy-induced neutropenia. The link to the survey was available internationally through social media and to their local societies over the period from July to September 2021.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We received 151 responses from 4 world regions: 58.9, 9.9, 11.3, and 15.2% from the Mena area, Russia, Europe, and Asia. The responses deviated from the guideline-driven practice as G-CSF was the most chosen option for intermediate risk that was statistically different based on the academic background of the treating physician. Half of the responders ignored patients and disease risk factors in the intermediate-risk cases that trend was statistically different based on the geographical distribution. The steroid was a valid option for intermediate and low-risk as per oncologists practicing in Russia. COVID-19 pandemic positively affected the rate of prescription of G-CSF as expected.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The disparities in the routine practice of oncologists based on their geographical and academic backgrounds highlight the need to analyze the underlying obstacles that hinder guideline-based practice like workload or lack of the proper knowledge.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00520-022-07421-8","type":"journal-article","created":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T13:11:39Z","timestamp":1667049099000},"page":"9921-9928","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Afebrile chemotherapy-induced neutropenia: an international survey spots oncologists\u2019 routine clinical practice versus the standard of care and the impact of COVID-19"],"prefix":"10.1007","volume":"30","author":[{"given":"Ereny Samwel Poles","family":"Saad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karima","family":"Oualla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narmin","family":"Talibova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Snezhanna","family":"Gening","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shady Gayed","family":"YousefYousef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,29]]},"reference":[{"issue":"12","key":"7421_CR1","first-page":"825","volume":"10","author":"MB Lustberg","year":"2012","unstructured":"Lustberg MB (2012) Management of neutropenia in cancer patients. Clin Adv hematol oncolo\u202f: H&O 10(12):825\u2013826","journal-title":"Clin Adv hematol oncolo : H&O"},{"issue":"2","key":"7421_CR2","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/cncr.11882","volume":"100","author":"J Crawford","year":"2004","unstructured":"Crawford J, Dale DC, Lyman GH (2004) Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 100(2):228\u2013237","journal-title":"Cancer"},{"issue":"13","key":"7421_CR3","doi-asserted-by":"publisher","first-page":"e3240","DOI":"10.1097\/MD.0000000000003240","volume":"95","author":"R-M Ma","year":"2016","unstructured":"Ma R-M et al (2016) Prognostic value of chemotherapy-induced neutropenia at the first cycle in invasive breast cancer. Med 95(13):e3240\u2013e3240","journal-title":"Med"},{"issue":"4","key":"7421_CR4","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1093\/cid\/ciq147","volume":"52","author":"AG Freifeld","year":"2011","unstructured":"Freifeld AG et al (2011) Executive summary: clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52(4):427\u2013431","journal-title":"Clin Infect Dis"},{"issue":"1","key":"7421_CR5","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","volume":"47","author":"MS Aapro","year":"2011","unstructured":"Aapro MS et al (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47(1):8\u201332","journal-title":"Eur J Cancer"},{"key":"7421_CR6","unstructured":"American Society of Clinical Oncology (2021) C.t.s.c., American Society of Clinical Oncology, 2021. Cancer Treat Support Care. https:\/\/www.asco.org\/asco-coronavirus-resources\/care-individuals-cancer-during-covid-19\/cancer-treatment-supportive-care"},{"key":"7421_CR7","unstructured":"4\/2021 (2021) N.g.G.f., NCCN guidelines Growth factors. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=3&id=1493"},{"issue":"28","key":"7421_CR8","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","volume":"33","author":"TJ Smith","year":"2015","unstructured":"Smith TJ et al (2015) Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 33(28):3199\u20133212","journal-title":"J Clin Oncol"},{"issue":"10","key":"7421_CR9","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1002\/cncr.21847","volume":"106","author":"NM Kuderer","year":"2006","unstructured":"Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106(10):2258\u20132266. https:\/\/doi.org\/10.1002\/cncr.21847","journal-title":"Cancer"},{"key":"7421_CR10","doi-asserted-by":"publisher","first-page":"100466","DOI":"10.1016\/j.ctarc.2021.100466","volume":"29","author":"J Crawford","year":"2021","unstructured":"Crawford J et al (2021) Use of prophylactic pegfilgrastim for chemotherapy-induced neutropenia in the US: a review of adherence to present guidelines for usage. Cancer Treat Res Commun 29:100466","journal-title":"Cancer Treat Res Commun"},{"issue":"1","key":"7421_CR11","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s00520-017-3854-x","volume":"26","author":"DC Dale","year":"2018","unstructured":"Dale DC et al (2018) A systematic literature review of the efficacy, effectiveness, and safety of filgrastim. Support Care Cancer 26(1):7\u201320","journal-title":"Support Care Cancer"},{"issue":"32","key":"7421_CR12","doi-asserted-by":"publisher","first-page":"3872","DOI":"10.1200\/JCO.2016.67.2899","volume":"34","author":"A Agiro","year":"2016","unstructured":"Agiro A et al (2016) Risk of neutropenia-related hospitalization in patients who received colony-stimulating factors with chemotherapy for breast cancer. J Clin Oncol 34(32):3872\u20133879","journal-title":"J Clin Oncol"},{"issue":"1","key":"7421_CR13","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1188\/10.CJON.81-86","volume":"14","author":"IQ Flores","year":"2010","unstructured":"Flores IQ, Ershler W (2010) Managing neutropenia in older patients with cancer receiving chemotherapy in a community setting. Clin J Oncol Nurs 14(1):81\u201386","journal-title":"Clin J Oncol Nurs"},{"issue":"7","key":"7421_CR14","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1177\/1078155218799859","volume":"25","author":"H Baig","year":"2019","unstructured":"Baig H et al (2019) Appropriateness of granulocyte colony-stimulating factor use in patients receiving chemotherapy by febrile neutropenia risk level. J Oncol Pharm Pract\u202f: Off Publ Int Soc Oncol Pharm Pract 25(7):1576\u20131585","journal-title":"J Oncol Pharm Pract : Off Publ Int Soc Oncol Pharm Pract"},{"issue":"6","key":"7421_CR15","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1177\/1078155218792698","volume":"25","author":"AR Zullo","year":"2019","unstructured":"Zullo AR et al (2019) Overuse and underuse of pegfilgrastim for primary prophylaxis of febrile neutropenia. J Oncol Pharm Pract 25(6):1357\u20131365","journal-title":"J Oncol Pharm Pract"},{"key":"7421_CR16","doi-asserted-by":"publisher","unstructured":"Griffiths EA, Alwan LM, Bachiashvili K, Brown A, Cool R, Curtin P, Geyer MB, Gojo I, Kallam A, Kidwai WZ, Kloth DD, Kraut EH, Lyman GH, Mukherjee S, Perez LE, Rosovsky RP, Roy V, Rugo HS, Vasu S, Wadleigh M, Westervelt P, Becker PS (2020) Considerations for use of hematopoietic growth factors in patients with cancer related to the COVID-19 pandemic. J Natl Compr Canc Netw: 1\u20134. https:\/\/doi.org\/10.6004\/jnccn.2020.7610","DOI":"10.6004\/jnccn.2020.7610"},{"issue":"15","key":"7421_CR17","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1016\/j.ejca.2006.05.002","volume":"42","author":"MS Aapro","year":"2006","unstructured":"Aapro MS et al (2006) EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 42(15):2433\u20132453","journal-title":"Eur J Cancer"},{"key":"7421_CR18","unstructured":"FACTORS NGG (2021) NCCN guidelines growth factors 4\\2021. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=3&id=1493"},{"issue":"3","key":"7421_CR19","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.critrevonc.2013.12.006","volume":"90","author":"GH Lyman","year":"2014","unstructured":"Lyman GH, Abella E, Pettengell R (2014) Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: a systematic review. Crit Rev Oncol Hematol 90(3):190\u2013199","journal-title":"Crit Rev Oncol Hematol"},{"issue":"21","key":"7421_CR20","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1161\/01.CIR.98.21.2307","volume":"98","author":"M Nakagawa","year":"1998","unstructured":"Nakagawa M et al (1998) Glucocorticoid-induced granulocytosis. Circulation 98(21):2307\u20132313","journal-title":"Circulation"},{"key":"7421_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40780-016-0072-5","volume":"3","author":"S Itai","year":"2017","unstructured":"Itai S et al (2017) Co-administration of dexamethasone increases severity and accelerates onset day of neutropenia in bladder cancer patients on methotrexate, vinblastine, adriamycin and cisplatin chemotherapy: a retrospective cohort study. J Pharm health care Sci 3:3\u20133","journal-title":"J Pharm health care Sci"},{"issue":"8","key":"7421_CR22","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1016\/j.jgo.2020.07.008","volume":"11","author":"NML Battisti","year":"2020","unstructured":"Battisti NML et al (2020) Adapting care for older cancer patients during the COVID-19 pandemic: recommendations from the International Society of Geriatric Oncology (SIOG) COVID-19 Working Group. J Geriatr Oncol 11(8):1190\u20131198","journal-title":"J Geriatr Oncol"},{"issue":"11","key":"7421_CR23","doi-asserted-by":"publisher","first-page":"3691","DOI":"10.1007\/s00520-018-4224-z","volume":"26","author":"A Razzaghdoust","year":"2018","unstructured":"Razzaghdoust A, Mofid B, Moghadam M (2018) Development of a simplified multivariable model to predict neutropenic complications in cancer patients undergoing chemotherapy. Support Care Cancer 26(11):3691\u20133699","journal-title":"Support Care Cancer"},{"issue":"6","key":"7421_CR24","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1081\/CNV-100104288","volume":"19","author":"CL Bennett","year":"2001","unstructured":"Bennett CL et al (2001) Economic analysis of granulocyte colony stimulating factor as adjunct therapy for older patients with acute myelogenous leukemia (AML): estimates from a Southwest Oncology Group Clinical Trial. Cancer Invest 19(6):603\u2013610","journal-title":"Cancer Invest"},{"issue":"1","key":"7421_CR25","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3109\/10428194.2013.791984","volume":"55","author":"J-C Ianotto","year":"2014","unstructured":"Ianotto J-C et al (2014) Biosimilars of filgrastim in autologous stem cell transplant: reduction in granulocyte-colony stimulating factor costs, but similar effects on bone marrow recovery. Leuk Lymphoma 55(1):74\u201377","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"7421_CR26","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1200\/JOP.2012.000662","volume":"9","author":"GE Waters","year":"2013","unstructured":"Waters GE et al (2013) Comparison of pegfilgrastim prescribing practice to national guidelines at a university hospital outpatient oncology clinic. J Oncol Pract 9(4):203\u2013206","journal-title":"J Oncol Pract"},{"issue":"30","key":"7421_CR27","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1200\/JCO.18.00374","volume":"36","author":"RA Taplitz","year":"2018","unstructured":"Taplitz RA et al (2018) Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update. J Clin Oncol 36(30):3043\u20133054","journal-title":"J Clin Oncol"},{"issue":"21","key":"7421_CR28","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1200\/JCO.2006.08.8823","volume":"25","author":"NM Kuderer","year":"2007","unstructured":"Kuderer NM et al (2007) Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol\u202f: Off J Am Soc Clin Oncol 25(21):3158\u20133167","journal-title":"J Clin Oncol : Off J Am Soc Clin Oncol"},{"key":"7421_CR29","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","volume":"395","author":"F Zhou","year":"2020","unstructured":"Zhou F, Yu T, Du R (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395:1054\u20131062","journal-title":"Lancet"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-07421-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-022-07421-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-07421-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T13:24:11Z","timestamp":1669901051000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-022-07421-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,29]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["7421"],"URL":"https:\/\/doi.org\/10.1007\/s00520-022-07421-8","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,29]]},"assertion":[{"value":"23 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}